<code id='50924260AC'></code><style id='50924260AC'></style>
    • <acronym id='50924260AC'></acronym>
      <center id='50924260AC'><center id='50924260AC'><tfoot id='50924260AC'></tfoot></center><abbr id='50924260AC'><dir id='50924260AC'><tfoot id='50924260AC'></tfoot><noframes id='50924260AC'>

    • <optgroup id='50924260AC'><strike id='50924260AC'><sup id='50924260AC'></sup></strike><code id='50924260AC'></code></optgroup>
        1. <b id='50924260AC'><label id='50924260AC'><select id='50924260AC'><dt id='50924260AC'><span id='50924260AC'></span></dt></select></label></b><u id='50924260AC'></u>
          <i id='50924260AC'><strike id='50924260AC'><tt id='50924260AC'><pre id='50924260AC'></pre></tt></strike></i>

          
          WSS
          Adam's take main illustration
          Molly Ferguson/STAT

          Biotech is awash in PIPEs.

          The numbers behind these privately negotiated purchases of public-company stock are astounding. By my count, there have been 30 PIPE transactions involving public biotechs and institutional investors (mostly hedge funds) that have raised $4 billion in the first two months of the year.

          advertisement

          Just this week, five biotechs have brought in a combined $950 million via PIPEs, including Denali Therapeutics raising $500 million, the largest such financing this year. Crinetics Pharmaceuticals raised $350 million.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          comprehensive